Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) – Pipeline Review, H2 2016’, provides an overview of the Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy)

The report reviews pipeline therapeutics for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) therapeutics and enlists all their major and minor projects

The report assesses Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Biscayne Pharmaceuticals Inc

GW Pharmaceuticals Plc

INSYS Therapeutics Inc

OPKO Health Inc

PTC Therapeutics Inc

Sage Therapeutics Inc

Xenon Pharmaceuticals Inc

Zogenix Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Overview 7

Therapeutics Development 8

Pipeline Products for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Overview 8

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Therapeutics under Development by Companies 9

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline Products Glance 10

Late Stage Products 10

Clinical Stage Products 11

Early Stage Products 12

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Products under Development by Companies 13

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Companies Involved in Therapeutics Development 14

Biscayne Pharmaceuticals Inc 14

GW Pharmaceuticals Plc 15

INSYS Therapeutics Inc 16

OPKO Health Inc 17

PTC Therapeutics Inc 18

Sage Therapeutics Inc 19

Xenon Pharmaceuticals Inc 20

Zogenix Inc 21

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Therapeutics Assessment 22

Assessment by Monotherapy Products 22

Assessment by Target 23

Assessment by Mechanism of Action 25

Assessment by Route of Administration 27

Assessment by Molecule Type 29

Drug Profiles 31

Antisense Oligonucleotide for Dravet Syndrome - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

ataluren - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

BIS-001 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

cannabidiol - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

cannabidiol - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

CUR-1916 - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

fenfluramine hydrochloride - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

SAGE-217 - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

Small Molecule to Block Nav1.6 for Dravet Syndrome - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Dormant Projects 58

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Product Development Milestones 59

Featured News & Press Releases 59

Nov 22, 2016: New Data on Zogenixs ZX008 for Lennox Gastaut Syndrome & Dravet Syndrome to be Presented at 70th Annual American Epilepsy Society Meeting 59

Oct 24, 2016: Newly Published Data Show Biscayne Pharmaceuticals' Novel Antiepileptic Drug Can Eliminate Seizures In Models Of Dravet Syndrome 60

Jun 28, 2016: Biscayne Pharmaceuticals Presents Data On Novel Antiepileptic Agent BIS-001 AT EILAT Conference On New Antiepileptic Drugs 61

Jun 27, 2016: GW Pharmaceuticals Announces Positive Phase 3 Pivotal Trial Results for Epidiolex (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome 62

Jun 08, 2016: Xenon Pharmaceuticals Presents Update on Nav1.6 Sodium Channel Inhibitor at the Jefferies 2016 Healthcare Conference 64

Jun 07, 2016: Zogenix Announces Initiation of Multi-National Phase 3 Clinical Trial for ZX008 in Dravet Syndrome 64

May 05, 2016: Zogenix Announces ZX008 New Efficacy and Safety Data for Treatment of Seizures in Dravet Syndrome 65

Apr 21, 2016: New Data on Zogenix ZX008 for Dravet Syndrome to be Presented at 14th International Child Neurology Congress 66

Mar 14, 2016: GW Pharmaceuticals Announces Positive Phase 3 Pivotal Study Results for Epidiolex (cannabidiol) 66

Feb 25, 2016: Edison Issues ADR Update on GW Pharmaceuticals 68

Jan 19, 2016: Zogenix Receives Fast Track Designation From FDA for Development of ZX008 in Dravet Syndrome 68

Jan 11, 2016: Zogenix Announces Initiation of Phase 3 Program for ZX008 in Dravet Syndrome 69

Dec 14, 2015: Zogenix Announces FDA Acceptance of Investigational New Drug Application for ZX008 Phase 3 Clinical Trial in Dravet Syndrome 69

Dec 07, 2015: Biscayne Pharmaceuticals Presents Data At 2015 AES Meeting Confirming BIS-001 Is A Novel Mechanism, Highly Potent And Well-Tolerated Anti-Epileptic Drug 70

Dec 07, 2015: GW Pharmaceuticals Announces New Physician Reports of Epidiolex Treatment Effect in Children and Young Adults With Treatment-Resistant Epilepsy 70

Appendix 74

Methodology 74

Coverage 74

Secondary Research 74

Primary Research 74

Expert Panel Validation 74

Contact Us 74

Disclaimer 75

List of Tables

List of Tables

Number of Products under Development for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy), H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 11

Comparative Analysis by Early Stage Development, H2 2016 12

Products under Development by Companies, H2 2016 13

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) – Pipeline by Biscayne Pharmaceuticals Inc, H2 2016 14

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) – Pipeline by GW Pharmaceuticals Plc, H2 2016 15

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) – Pipeline by INSYS Therapeutics Inc, H2 2016 16

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) – Pipeline by OPKO Health Inc, H2 2016 17

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) – Pipeline by PTC Therapeutics Inc, H2 2016 18

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) – Pipeline by Sage Therapeutics Inc, H2 2016 19

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) – Pipeline by Xenon Pharmaceuticals Inc, H2 2016 20

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) – Pipeline by Zogenix Inc, H2 2016 21

Assessment by Monotherapy Products, H2 2016 22

Number of Products by Stage and Target, H2 2016 24

Number of Products by Stage and Mechanism of Action, H2 2016 26

Number of Products by Stage and Route of Administration, H2 2016 28

Number of Products by Stage and Molecule Type, H2 2016 30

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) – Dormant Projects, H2 2016 58

List of Figures

List of Figures

Number of Products under Development for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy), H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Clinical Stage Development, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 12

Assessment by Monotherapy Products, H2 2016 22

Number of Products by Targets, H2 2016 23

Number of Products by Stage and Targets, H2 2016 23

Number of Products by Mechanism of Actions, H2 2016 25

Number of Products by Stage and Mechanism of Actions, H2 2016 25

Number of Products by Routes of Administration, H2 2016 27

Number of Products by Stage and Routes of Administration, H2 2016 27

Number of Products by Molecule Types, H2 2016 29

Number of Products by Stage and Molecule Types, H2 2016 29

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports